Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 16/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221112 | 0.79 | BCAT2 (0.46) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL2221108 | 0.79 | AVPR2 (0.61) | SMOMEN1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL27902120 | 0.79 | SMO (0.43) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL14553224 | 0.78 | NPC1 (0.78) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL27965805 | 0.76 | CHRNB2 (0.60) | MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL7469465 | 0.75 | KIF11 (0.49) | MEN1ALDH1A1KMT2A | |
| SCHEMBL13210669 | 0.75 | SMO (0.66) | SMOMEN1KMT2AGRM4JAK2 | |
| SCHEMBL30640575 | 0.74 | SMO (0.63) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL26673836 | 0.74 | SMO (0.71) | SMOMEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL2117583 | 0.74 | SMO (0.75) | SMOMEN1CYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| EP-2521451-A1 | HEDGEHOG INHIBITORS | Selexagen Therapeutics, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011085128-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085128-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SHH, SMO, GLI1 | SMO 2/4885MEN1 1286/4885ALDH1A1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.